News | November 14, 2022
Supriya Lifescience Q2 FY2023 profit slips to Rs. 16.86 Cr
The company has reported total income of Rs. 114.77 crores during the period ended September 30, 2022.
The company has reported total income of Rs. 114.77 crores during the period ended September 30, 2022.
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
Cyclophosphamide Capsules, 25 mg and 50 mg, have an estimated market size of US$ 8 million for twelve months ending Sep 2022 according to IQVIA.
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
The company has reported total income of Rs. 61.64 crores during the period ended September 30, 2022.
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
The company is making its entry into the Hyderabad market through its unique asset-light business model
The Group will continue to make proactive investments of its management resources in the life science business
The team will assist the State Health Authorities in instituting public health measures and facilitate operationalization of requisite control and containment measures
Subscribe To Our Newsletter & Stay Updated
